Ftse Mib
34.460,52
0,00%
DAX
18.682,11
0,00%
S&P 500
5.307,01
-0,27%
NASDAQ
16.801,54
-0,18%
Bitcoin
69.472,47
0,53%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Sesen Bio Inc (SESN) Sesen Bio Inc (SESN) Notizie

SESN

Sesen Bio (SESN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SESN
DataOraFonteTitoloSimboloCompagnia
10/08/202313:30PR Newswire (US)Carisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:SESNSesen Bio Inc
06/03/202318:41Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:SESNSesen Bio Inc
06/03/202318:35Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SESNSesen Bio Inc
03/03/202317:07Edgar (US Regulatory)Sec Staff Action/letter (sec Staff)NASDAQ:SESNSesen Bio Inc
02/03/202317:32Business WireSesen Bio Stockholders Approve Merger with Carisma TherapeuticsNASDAQ:SESNSesen Bio Inc
28/02/202314:03Edgar (US Regulatory)Annual Report (10-k)NASDAQ:SESNSesen Bio Inc
28/02/202314:00Business WireSesen Bio Reports Fourth Quarter and Full-Year 2022 Financial ResultsNASDAQ:SESNSesen Bio Inc
21/02/202315:00Business WireLeading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote “FOR” All Proposals to Approve Pending Merger With CarismaNASDAQ:SESNSesen Bio Inc
16/02/202323:06Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:SESNSesen Bio Inc
16/02/202322:42Business WireLeading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special MeetingNASDAQ:SESNSesen Bio Inc
16/02/202314:00Business WireSesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending MergerNASDAQ:SESNSesen Bio Inc
15/02/202322:55Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:SESNSesen Bio Inc
15/02/202314:00Business WireBML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma TherapeuticsNASDAQ:SESNSesen Bio Inc
14/02/202322:40Edgar (US Regulatory)Registration Pursuant to Securities Act Rule 462(b) of up to an Additional 20% of Securities for an Offering That Was Registered on a Form S-4 (s-4mef)NASDAQ:SESNSesen Bio Inc
14/02/202314:00Business WireSesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending MergerNASDAQ:SESNSesen Bio Inc
09/02/202318:10Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:SESNSesen Bio Inc
02/02/202322:30Business WireSesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics MergerNASDAQ:SESNSesen Bio Inc
30/01/202314:00Business WireSesen Bio Receives NASDAQ Delisting NoticeNASDAQ:SESNSesen Bio Inc
26/01/202314:00Business WireSesen Bio Reiterates Confidence that Pending Merger with Carisma is in Best Interests of StockholdersNASDAQ:SESNSesen Bio Inc
25/01/202316:36Business WireInvestor Group Issues Letter to the Boards of Sesen Bio and Carisma Rejecting Their Apparent Attempt to Purchase Merger SupportNASDAQ:SESNSesen Bio Inc
20/01/202312:02Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:SESNSesen Bio Inc
19/01/202322:28Business WireSesen Bio Files Definitive Proxy Statement and Mails Letter to Stockholders in Connection with Pending Merger with Carisma TherapeuticsNASDAQ:SESNSesen Bio Inc
05/01/202314:00Business WireInvestor Group Issues Letter to Sesen Bio’s Board of Directors Regarding Intent to Vote AGAINST Proposed Carisma MergerNASDAQ:SESNSesen Bio Inc
04/01/202314:00Business WireSesen Bio Reiterates Confidence in Pending Merger with Carisma TherapeuticsNASDAQ:SESNSesen Bio Inc
03/01/202314:00Business WireInvestor Group Reiterates Intent to Vote AGAINST Sesen Bio’s Value-Destructive Merger with CarismaNASDAQ:SESNSesen Bio Inc
29/12/202222:33Business WireSesen Bio and Carisma Therapeutics Announce Substantial Increase to Expected Special Cash Dividend in Connection with Pending MergerNASDAQ:SESNSesen Bio Inc
22/11/202212:02Edgar (US Regulatory)Registration Statement for Securities to Be Issued in Business Combination Transactions (s-4/a)NASDAQ:SESNSesen Bio Inc
07/11/202214:00Business WireSesen Bio Reports Third Quarter 2022 Financial Results and Business UpdateNASDAQ:SESNSesen Bio Inc
14/10/202223:10Edgar (US Regulatory)Securities Registration: Business Combination (s-4)NASDAQ:SESNSesen Bio Inc
21/09/202214:00Business WireSesen Bio and Carisma Therapeutics Announce Merger AgreementNASDAQ:SESNSesen Bio Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SESN

La tua Cronologia

NASDAQ
AAXVJXX
Hsbc Bank Usa Na Capped ...
EU
IPSAA
Ipsos SA 2.875% 21sep2025
COIN
CNTUSD
BIT
P1Y144
NLBNPIT1Y144 20991231 15...
BIT
P20OJ3
NLBNPIT20OJ3 20240621 20
EU
FR0010804773
Cmcicfctfrn29sep16 Bonds
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network